|
Luminex Corporation (NASDAQ: LMNX) is a biotechnology company based in Austin, Texas, with offices in Madison, WI, Toronto, the Netherlands, Shanghai and Tokyo. Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life-sciences industry. Nachum "Homi" Shamir has served as Luminex's President and Chief Executive Officer since October, 2014. Luminex was recognized by Forbes magazine as one of the top 25 fastest growing technology companies in the US. Luminex's xMAP® (Multi-Analyte Profiling) technology, is an open architecture, multiplexing technology, which allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. xMAP technology is currently being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. In addition to the xMAP technology, Luminex has its proprietary MultiCode® technology, used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. ==Products and Applications== Luminex Corporation currently owns 315 issued patents worldwide, including over 124 issued patents in the United States based on its multiplexing xMAP platform. Luminex's proprietary multiplex bead-based immunoassay testing platform simultaneously measures multiple analytes by exciting a sample with a laser, and subsequently analyzing the wavelength of emitted light. Luminex's MAGPIX platform utilizes LED technology and digital photography to analyze,"color-coded magnetic microspheres". In 2008 Luminex received FDA 510(k) clearance for its xTAG Respiratory Viral Panel which allows doctors to test for the presence of 12 respiratory viruses with a very high degree of accuracy in a matter of hours, and has been proven to provide an increase in accuracy over in-house nucleic acid amplification testing in the diagnosis of respiratory virus infections.〔(【引用サイトリンク】url=http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm074349.htm )〕 Luminex's xTAG Gastrointestinal Pathogen Panel was granted a CE mark by the European Union in 2012 and received FDA and Health Canada clearance in early 2013.〔(【引用サイトリンク】url=http://www.genengnews.com/gen-news-highlights/luminex-xtag-gastrointestinal-pathogen-panel-gains-ce-mark/81245104/ )〕 Luminex also has an extensive portfolio of genetics assays focused on cystic fibrosis and pharmacogenetics. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Luminex Corporation」の詳細全文を読む スポンサード リンク
|